What question did this study set out to answer?

The study aims to investigate the clinical significance and effectiveness of KAT6 inhibitors in treating solid tumors.

February 20, 2026

KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress

SYShu YazakiMemorial Sloan Kettering Cancer Center

Key Points

The study aims to investigate the clinical significance and effectiveness of KAT6 inhibitors in treating solid tumors.
Phase III trial of Prifetrastat to assess clinical impacts.
Evaluation of KAT6 inhibitors across different solid tumor types, including breast cancer.
Development of mitigation strategies for treatment-related dysgeusia.
Initial data from the Prifetrastat study will inform KAT6 inhibitors' clinical significance.
KAT6 inhibitors may show varying effects based on tumor type due to different target spectrums.
Insights into KAT6-targeted therapies could lead to more personalized treatment approaches.

Abstract

A phase III study of Prifetrastat will provide initial data on the clinical significance of KAT6 inhibitors. The application of Prifetrastat and other KAT6 inhibitors to wider breast cancer subpopulations and other solid tumors is anticipated. Additionally, mitigation strategies for dysgeusia and clinically available response-predictive biomarkers should be developed. KAT6 inhibitors with different target spectra, including KAT6A-selective and KAT6/7 inhibitors, may exhibit differential efficacy and safety profiles, offering deeper insights into KAT6-targeted therapy.

Ask AI

Helpful

Bookmark

View Full Paper